Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna stock nearly tripled on August 19, climbing 177% to $174.38 after the company and Merck announced positive Phase 3 trial results for intismeran, a personalized mRNA cancer vaccine. The trial met its primary goal of extending recurrence-free survival in melanoma patients when combined with Merck’s Keytruda immunotherapy. This marks the first successful late-stage study for any mRNA-based cancer therapy, a watershed moment for Moderna as it seeks growth beyond COVID vaccines.

The trial results and what they mean

The Phase 3 INTerpath-001 trial involved over 1,100 patients with high-risk melanoma whose tumors had been surgically removed. Intismeran, combined with Keytruda, significantly extended the time patients lived without melanoma returning compared to Keytruda alone. Earlier Phase 2 data showed a 49% reduction in recurrence risk and 59% reduction in metastasis risk. Merck and Moderna will present full data at an upcoming medical conference and plan to discuss regulatory filing with the FDA within months.

Why the stock jumped so sharply

Moderna’s 177% surge reflects investor relief after years of declining revenue post-COVID. The company’s year-to-date gain now stands at 445%, though shares remain down roughly two-thirds from a $484 peak in August 2021. The breakthrough demonstrates the commercial potential of personalized cancer treatment. Merck shares climbed 12% on the same news, reflecting the partnership’s value.

What Meyka data shows about the valuation

Meyka grades Moderna a B with a 12-month price forecast of $58.61, well below Wednesday’s $174.38 close. The stock’s RSI stands at 92.04, indicating overbought conditions. Analyst consensus leans bullish with five buy ratings against one sell, but the sharp spike has created a gap between market price and fundamental forecasts. The company trades at 30.4x sales and carries a negative earnings yield, reflecting its unprofitable status.

Regulatory path and next steps

The FDA has not yet approved intismeran. Full data will be submitted for regulatory review, with Dr. Ahmad Tarhini of H. Lee Moffitt Cancer Center predicting approval by early 2027. The Phase 3 trial will continue to assess overall survival benefits. Melanoma accounts for only 1% of skin cancers but causes the majority of skin cancer deaths, making this a significant unmet medical need.

Final Thoughts

Moderna’s 177% surge reflects genuine clinical progress, but Meyka’s B grade and $58.61 forecast suggest the rally has outpaced fundamentals. Investors should await full trial data and regulatory clarity before chasing the stock at current levels.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.